Thermo Fisher Scientific Partners With OpenAI To Integrate AI Across Drug Development, Clinical Trials, And Operations For Faster, Cost-Effective Medicine Delivery
Author: Benzinga Newsdesk | October 16, 2025 08:28am
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher's proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively.
Working with OpenAI, Thermo Fisher is focusing on accelerating scientific innovation, enhancing productivity and reducing complexity. As part of this collaboration, Thermo Fisher is embedding Open AI APIs (Application Programming Interfaces) into critical areas of its business - ranging from product development, service delivery, customer engagement and operational efficiency.
The collaboration will:
- Deploy OpenAI advanced capabilities to one of the highest impact initial focus areas - Thermo Fisher's industry leading PPD™ clinical research business - to significantly improve the cycle time of clinical trials and accelerate the time to bring new medicines to market, creating meaningful value for the industry.
- Leverage OpenAI capabilities and Thermo Fisher's expertise, to more quickly help identify therapies that are unlikely to succeed, which will enable customers to redirect investment and resources toward more promising opportunities.
- Integrate AI into Thermo Fisher's Accelerator™ Drug Development solution, an end-to-end approach spanning early development, Phase I–III clinical research, clinical manufacturing and supply and commercialization. This solution is designed to deliver greater speed, simplicity and scalability for customers.
- Launch frontier AI to Thermo Fisher colleagues, with ChatGPT Enterprise, making it easier to build confidence and fluency with these powerful tools.
Posted In: MSFT TMO
